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Background: Recently studies have demonstrated improved outcomes in patients undergoing nephron-sparing
surgery (NSS) for low stage renal tumors, thus NSS is widely accepted as the treatment option for these patients.
With NSS, there is a risk of renal hemorrhage and thus haemostatic agents may be routinely applied to the cut
surface of the kidney. Herein we compare two commercially available haemostatic agents applied intra-operatively
to the cut surface of the kidney. Post-operative outcomes (oncologic and non-oncologic) are reported.
Methods: The medical records of 23 patients with suspicious renal mass documented on axial imaging and who
underwent open NSS via a mini-subcostal incision were extensively reviewed. One of two haemostatic agents
(FlosealW, n = 11; AristaW, n = 12) was intra-operatively applied to the cut surface of the kidney. Chi-square and
T- student test was used to compare outcomes between the cohort of 11 patients who had FlosealW and the
12 patients who had AristaW.
Results: Median pre-operative size of renal mass was 4.3 cm (range 1.5-7.0 cm). Final pathology revealed 3
oncocytomas and 20 renal cell carcinoma (17 clear cell, 1 chromophobe and 2 papillary), pT1a = 14 and pT1b = 6.
Mean intra-operative blood loss and hospital stay between the FlosealW vs. AristaW cohorts did not significantly differ
(227 mL vs. 250 mL, p = 0.68 and 4.4 days vs. 4.5 days, p = 0.76, respectively). Intra-operative and post-operative
complications were not different between the two cohorts. No recurrences have been documented with a mean
follow-up of 18 months.
Conclusion: Along with meticulous surgical technique, the use of either haemostatic agent (FlosealW or AristaW) was
not associated with high rate of intra-operative or post-operative haemorrhage. Thus either haemostatic agent may be
successfully used during NSS.
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In 2012, it is estimated that 64,770 Americans will be di-
agnosed with cancer of the kidney resulting in approxi-
mately 13,570 deaths [1]. Interestingly, kidney cancer is
one of only a few cancers with an increasing incidence
over the past two decades [2]. Renal cell carcinoma
(RCC) accounts for over 85% of all kidney tumors,
which makes up 2-3% of all adult malignancies [3]. Ap-
proximately, 70% of RCCs are incidentally discovered on
axial imaging of the abdomen with >50% of RCCs being* Correspondence: deacdoc@aol.com
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reproduction in any medium, provided the orlow-stage (T1-T2 N0M0) [4,5]. Despite advancements in
drug discovery for advanced RCC, mortality rates have
not changed over the past two decades [6], however for
patients with low-stage disease, surgical extirpation of-
fers excellent 5-year survival rates of 95% [5].
Traditionally, surgical expiration of these low-stage tu-
mors was in the form of radical nephrectomy (i.e., removal
of kidney, Gerota’s fascia and ipsilateral adrenal gland) [7].
Then contemporary studies demonstrate that in select tu-
mors, adrenal sparing surgery [8] and nephron sparing
surgery (NSS) [9] could be effectively performed without
compromising oncologic outcomes. Recently studies have
demonstrated improved non-oncological outcomes in pa-
tients undergoing NSS for low-stage tumors [10]. Thus,
we currently find ourselves in the midst of a new era inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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center stage and widely accepted as the treatment option
for these patients.
It is not unusual to use haemostatic agents during pro-
cedures with a propensity for bleeding. NSS is one of
these procedures. Numerous haemostatic agents are
available for use. One such agent that has been widely
used over the past decade is FlosealW. FlosealW consists
of patented bovine-derived gelatin granules coated in
human-derived thrombin that work in combination to
form a stable clot at the bleeding site [11]. FlosealW,
FDA approved in 1999, expands approximately 20%
within about 10 minutes, giving predictable control dur-
ing and after surgery [12]. Another haemostatic agent,
AristaW, is a synthetic haemostatic compound that in-
cludes an absorbable haemostatic powder consisting of
Microporous Polysaccharide Hemospheres (MPHW).
Arista works through accelerating the intrinsic clotting
cascade by extracting fluid from blood, concentrating
serum proteins and platelets, which is the scaffolding for
the formation of a fibrin clot [13].
Earlier studies reported relatively high complication
rates associated with NSS [14], which have greatly reduced
over the past decade due to surgical refinement [15,16].
One such complication was haemorrhage related to the
surgery (intrao-perative or post-operative). Thus the suc-
cessful incorporation of a haemostatic agent, which may
be routinely applied to the cut surface of the kidney, may
prove to be advantageous. Herein we compare two com-
mercially available haemostatic agents applied intra-
operatively. Intra-operative and post-operative outcomes
(oncologic and non-oncologic) are reported.
Method
After MD Anderson Cancer Center Orlando institu-
tional review board approval with consent waiver, med-
ical records of patients who had undergone NSS for a
suspicious renal mass from December 2009 to Septem-
ber 2012 were extensively reviewed. Preferentially, non-
hilar, renal lesions < 7 cm were considered for NSS.
Using these selection criteria, our study cohort was com-
prised of 23 patients who underwent NSS. Clinical and
hospital records were reviewed for demographics, smok-
ing history, body mass index (BMI), comorbidities, pre-
operative and post-operative glomerular filtration rate
(GFR), intra-operative features, disease characteristics
and outcomes (oncologic and non-oncologic).
All patients had renal masses visualized and character-
ized by axial imaging (CT scan = 20, MRI scan = 2 and
CT scan/MRI scan = 1). Of the 23 patients with renal
masses, 3 renal masses were noted to be cystic masses
(Bosniak III = 2, size 3 cm and 5 cm and Bosniak IV = 1,
mean size 5.5 cm), while the remainder was solid. Ap-
proximately four weeks prior to NSS, patient had serumcreatinine drawn and GFR was calculated. In three of
the 23 patients, a percutaneous core biopsy of the renal
mass was performed demonstrating RCC (Clear cell car-
cinoma = 2 and papillary carcinoma = 1). All patients
underwent open mini-incision NSS.
Open NSS was performed as previously described [17]
with modification by one surgeon (CJR). Briefly, the
renal artery was clamped and renal parenchyma was
transected and the tumor excised with grossly negative
surgical margins. The surgical specimen was properly
orientated and sent immediately to pathology for frozen
section analysis, confirming negative surgical margins of
at least 1 mm. Next the argon beam laser was used to
extensively coagulate the cut surface of the renal cortex.
The incision of the kidney (cortex and medullae) was
then completely covered by either 5 ml of FlosealW in 11
patients which was the agent of choice from December
2009 to February 2011 or 3 grams of AristaW in 12 pa-
tients which was the agent of choice from March 2011
to the present. Into the renal defect, a large pledget of
SurgicelW was placed. Vertical mattress sutures, incorp-
orating the SurgicelW pledget, was placed to close the
renal defect.
Complications were graded with Clavien-Dindo Classi-
fication and were noted to be either intra-operative or
post-operative. Post-operative complications were classi-
fied as urological and nonurological (e.g., cardiac, gastro-
intestinal pulmonary, thromboembolic, incisional or
other). Urological complication was defined as signifi-
cant hemorrhage > 500 mL necessitating intervention or
transfusion, urine leakage (drainage of greater than
50 mL daily for more than one week with fluid biochem-
istry compatible with urine) and acute renal failure
(resulting in any dialysis, ureteral obstruction or kidney
loss) [10]. In addition, serum creatinine levels were
assessed four week after surgery and post-operative GFR
was calculated.
Chi-square and T- student test was used to compare
outcomes between the cohort of 11 patients who had
FlosealW and the 12 patients who had AristaW. P values less
than 0.05 were considered to be statistically significant. All
data were analyzed using SPSS software version 22.Results
Demographics, laboratory values and disease characteris-
tics of the entire cohort are summarized in Table 1. The
mean age of the entire cohort was 57.9 ± 10.4 years. The
majority of patients were male (57%), Caucasian (52%)
with left-sided lesions (78%). Median pre-operative size of
renal mass measured on axial imaging was 4.3 cm (range
1.5 - 7 cm). Mean BMI was 30.2 ± 4.5 kg/m2 and mean
pre-operative GFR was 82.0 ± 19.2 mL/min/1.73 m2. Re-
garding these demographics, laboratory values and disease

















Male:female 13:10 7:4 6:6 .51
Race 0.40
Caucasian 12 (52%) 5 (46%) 7 (58%)
African American 3 (13%) 1 (8%) 2 (17%)
Latinos 7 (31%) 5 (46%) 2 (17%)
Others 1 (4%) 0 (0%) 1 (8%)
Tobacco history 12 (52%) 6 (55%) 6 (50%) 0.82












Side of renal mass (R/L) 5/18 1/10 4/8 0.15




4.4 ± 1.8 4.2 ± 1.4 0.70















9 (82%) 8 (66%)
Papillary 2 (9%) 0 (%) 2 (17%)
Chromophone 1 (4%) 1 (9%) 0 (0%)




7 (70%) 7 (70%)
T1b 6 (30%) 3 (30%) 3 (30%)
Furhman grade 0.14
1 8 (40%) 6 (60%) 2 (20%)
2 11
(55%)
4 (40%) 7 (70%)
3 1 (5%) 0 (0%) 1 (10%)
4 0 (0%) 0 (0%) 0 (0%)
Pos. surgical margin N.A.
0 (0%) 0 (0%) 0 (0%)









Hospital stay/days 4.5 ± 0.9 4.4 ± 1.2 4.5 ± 0.7 0.76
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fer significantly.
The median cool ischemia time was 30.8 minutes in
the FlosealW group compared to 35.4 minutes in the
AristaW group (p = 0.075). Mean intra-operative blood
loss was 227 mL in the FlosealW group compared to
250 mL in the AristaW group (p = 0.68).
Post-operative disease characteristics and laboratory
values of the entire cohort are summarized in Table 2.
The majority of patients had clear cell variant of RCC
(74%), pathologic stage T1a (70%) and Fuhrman grade 2
(55%). The previously described Bosniak cysts were
found to be clear cell RCC. Disease characteristics were
similar between the two groups. Mean post-operative
GFR was 66.9 ± 21.8 mL/min/1.73 m2 in the Floseal co-
hort and 74.5 ± 15.4 mL/min/1.73 m2 in the Arista
group, p = 0.34). Mean hospital stay between the
FlosealW vs. AristaW cohorts did not significantly differ
(4.4 days vs. 4.5 days, p = 0.76, respectively).
Seven complications (two intra-operative and five post-
operative) were noted in 6 (26%) of the patients. The two
intra-operative complications included transfusion for
500 mL blood loss (Clavien II) and small ipsilateral
pneumothorax (Clavien I). The pnuemothorax was man-
aged conservatively with complete resolution noted over
two weeks. The five post-operative complications included
prolonged urinary leak of 10 days (Clavien I) and readmis-
sion with 30 days for chest pain (Clavien I) (both in one
patient), ileus = 1 (Clavien II), and >25% reduction in
GFR-2 = 2 (Clavien I) (Table 3). No difference was noted
in post-operative complications in patients in the FlosealW
group compared to the AristaW group. No post-operative
mortalities were noted. No recurrences have been docu-
mented with a mean follow-up of 18 months.
Discussion
Nephron-sparing surgery was initially used to treat pa-
tients with anatomically or functionally solitary kidney,
bilateral renal masses or hereditary renal cell carcinoma
or patients affected by comorbidities that might impair
renal function, such as diabetes, hypertension, athero-
sclerosis, calculous renal disease, chronic pyelonephritis,
ureteral reflux, renal artery stenosis and other causes of
glomerulopathies [14,17]. Today, patients without any of
the above conditions may be considered for NSS, since
cancer specific survival and metastasis free survival are
similar in all T1N0M0 renal tumors treated with NSS or
radical nephrectomy [18-21]. Furthermore, NSS is asso-
ciated with a decreased risk of chronic kidney disease,
cardiovascular events and mortality when compared to
radical nephrectomy [10].
Open NSS can be by far more complex than radical
nephrectomy. Several decades ago, reports on open NSS
described a greater risk of complications including: acute













Excessive blood loss with
transfusion
1 0 1 0.32
Prolonged urinary leak 1~ 0 1 0.32
>25% reduction in GFR 2 2 0 0.12
Other^ 0 0 0 N/A
Non-urologic
Ileus 1 0 1 0.32
Wound infection 0 0 0 N/A
Other* 3~ 1 2 0.59
~, one patient had two complications (readmission within 30 days for chest
pain with a negative evaluation and prolonged urinary drainage-drain
removed on POD#10.
^,acute renal failure resulting in any dialysis, ureteral obstruction or
kidney loss.
*, cardiac, gastrointestinal pulmonary, thromboembolic, incisional or other.
N/A, not applicable.
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[14,22]. For example, Campbell et al. described complica-
tion rates after open NSS of 37% for symptomatic tumors
and of 22% for incidental tumors [14]. Complication rates
associated with NSS (e.g., overall morbidity rate, hospital
stay, blood losses, and frequency of acute renal failure)
have decreased significantly [23,24], which may be attrib-
uted to the greater experience of the urologist [25] or per-
haps due to the incorporation of various new technologies
(i.e., hemostatic agents, lasers, etc.) into the procedure.
Interestingly, the use of NSS has increased only by 20%
from 1995 to 2007 with 72% of Medicare beneficiaries
with localized tumors being managed with radical neph-
rectomy [26]. With the comparable survival rates andFigure 1 Pre-operative and post-operative CT scan of patient who un
demonstrated 4 cm solid, exophytic mass in the lower pole of the left kidn
patient presented to Emergency Department (ED) with abdominal pain. Pa
abnormal urinalysis. However, CT scan in the ED was interrupted as an abs
collection. C) Due to the unimpressive clinical scenario, no intervention wa
visit to the ED noted healing surgical site. Arrow illustrating reduction in fludecreasing morbidities, it is unclear why NSS remains
underutilized in this population.
In our small cohort, we were able to compare the use
of FlosealW and AristaW in this cohort. Increased risk of
bleeding was not evident with the use of the new
haemostatic agent, AristaW. Haemostatic agents such as
FlosealW or AristaW in addition with an adequate surgical
technique were adequate in maintaining post-operative
haemostasis. No patient was noted to have a clinical
post-operative bleed. Several benefits exist with AristaW.
First, no mixing is required and thus the agent can be
used immediately. Second, AristaW is a synthetic haemo-
static reagent and FlosealW is made from human plasma,
the latter may carry a risk for virus or prion infection.
This is the first report of AristaW being used in a NSS.
Radiologic imaging after complex renal surgery may be
problematic and thus urologist may have to clearly de-
scribe surgical technique to the radiologist interpreting
post-operative scans. For example, we noticed on several
occasions SurgicelW pledgets have a space occupying low
attenuation appearance, which could mimic an abscess
(Figure 1). Thus we must stress that in the immediate
post-operative setting (i.e., with 30 days), unless the pa-
tient has fever, elevated white blood cells count that cau-
tion must be exercised in over interpreting post-operative
imaging.
Our study has several limitations. First, it is a small
retrospective study from a single center performed by one
surgeon. Next, our follow-up was limited (mean follow-up
of 18 months) to reliably report any differences in onco-
logic outcomes. This short follow-up, however, is sufficient
when assessing intra-operative and post-operative out-
comes. Lastly, we devoted significant attention to the cut
surface of the kidney (i.e., tying off lobar vessels, coagulat-
ing renal cortex with Argon laser in addition to placing aderwent NSS. A) Pre-operative CT scan with intravenous contrast
ey. Patient underwent an open left NSS. B) Four weeks after NSS,
tient was without fever/chills, elevated white blood cell count or an
cess at the surgical site in the left kidney. Arrow illustrating fluid
s performed and a repeat CT scan of the abdomen 8 weeks after the
id collection and healing parenchyma.
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agent cannot be answered in this study.
Conclusion
In conclusion, along with meticulous surgical technique,
the use of either haemostatic agent (FlosealW or AristaW)
was not associated with high rate of intra-operative or
post-operative haemorrhage. When requiring the appli-
cation of a haemostatic agent during NSS, either haemo-
static agent studied may be successfully employed.
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